Biotechnology and Pharmaceutical Services Outsourcing Market Report 2026

The biotechnology and pharmaceutical services outsourcing market size has grown strongly in recent years. It will grow from $71.87 billion in 2025 to $77.21 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to rising complexity of drug development pipelines, increasing regulatory scrutiny across markets, expansion of clinical trial activities, growth of biotech startups, need for specialized external expertise.

The biotechnology and pharmaceutical services outsourcing market size is expected to see strong growth in the next few years. It will grow to $101.56 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to increasing biologics and cell therapy development, rising demand for flexible outsourcing partnerships, growing use of ai in drug discovery services, expansion of emerging market pharma manufacturing, increasing focus on speed-to-market strategies. Major trends in the forecast period include increasing outsourcing of specialized drug development services, rising demand for regulatory and compliance support, growing adoption of data-driven r&d outsourcing models, expansion of end-to-end lifecycle management services, enhanced focus on cost and time optimization.

The increasing activity in clinical research is expected to drive the growth of the biotechnology and pharmaceutical services outsourcing market in the coming years. Clinical research involves systematic investigations with human participants, aimed at improving the understanding of health conditions and evaluating the safety and efficacy of medical interventions. The rise in clinical research is largely fueled by the growing burden of chronic diseases, which necessitates the development and testing of new therapies to improve patient care. Outsourcing biotechnology and pharmaceutical services supports clinical research by offering access to specialized expertise and advanced infrastructure, ensuring efficient, cost-effective, and compliant execution of trials on a global scale. For example, in November 2023, according to the Association of the British Pharmaceutical Industry (ABPI), a UK-based trade association, data from system partners indicated a 15% increase in annual recruitment for industry clinical trials in the UK, rising from 36,722 participants in 2021/22 to 42,088 in 2022/23. Therefore, the increasing activity in clinical research is fueling the growth of the biotechnology and pharmaceutical services outsourcing market.

Key companies in the biotechnology and pharmaceutical services outsourcing market are focusing on developing advanced solutions, such as cloud-based platforms, to enable real-time collaboration and remote access. Cloud-based platforms are internet-enabled systems that allow users to access computing resources - such as storage, software, and processing power - without relying on local servers or devices. For instance, in March 2023, Charles River Labs, a US-based non-clinical contract research organization, launched Apollo, a cloud-based platform designed to enhance toxicology studies. The platform provides clients with easy access to extensive study data to support safety and toxicology evaluations. It includes self-service tools that allow users to monitor study progress, analyze data, and retrieve essential documents independently, along with a quoting feature that facilitates more accurate and efficient budget planning.

In July 2024, IntegriChain, a US-based software company, acquired Federal Compliance Solutions (FCS) for an undisclosed amount. Through this acquisition, IntegriChain aims to strengthen its capabilities in commercialization, government pricing, and revenue operations management. Federal Compliance Solutions is a US-based provider of biotechnology and pharmaceutical services outsourcing.

Major companies operating in the biotechnology and pharmaceutical services outsourcing market are Thermo Fisher Scientific Inc, LabCorp Holdings, IQVIA Inc, ICON Plc, Eurofins Scientific SE, Lonza Group Ltd, Syneos Health, Catalent Inc, Charles River Laboratories, Samsung Biologics Co Ltd, WuXi Biologics, Recipharm AB, Medpace Holdings Inc, Curia Inc, CordenPharma Corp, Parexel International Ltd, Lachman Consultants, Concept Heidelberg GmbH, The Quantic Group Ltd, PRA Health Sciences, PPD Inc, Covance Inc, Alcami Corporation, Pharmalex GmbH.

North America was the largest region in the biotechnology and pharmaceutical services outsourcing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biotechnology and pharmaceutical services outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biotechnology and pharmaceutical services outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the biotechnology and pharmaceutical services outsourcing market by increasing costs of imported laboratory equipment, analytical instruments, IT infrastructure, and specialized consumables used in outsourced research and regulatory services. Service providers in North America and Europe are most affected due to cross-border sourcing of advanced tools, while Asia-Pacific faces cost pressures on export-oriented service delivery. These tariffs are raising operational costs and contract pricing for sponsors. At the same time, they are encouraging localization of service infrastructure, regional capacity expansion, and increased investment in domestic life sciences service ecosystems.

The biotechnology and pharmaceutical services outsourcing market research report is one of a series of new reports that provides biotechnology and pharmaceutical services outsourcing market statistics, including biotechnology and pharmaceutical services outsourcing industry global market size, regional shares, competitors with a biotechnology and pharmaceutical services outsourcing market share, detailed biotechnology and pharmaceutical services outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the biotechnology and pharmaceutical services outsourcing industry. This biotechnology and pharmaceutical services outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biotechnology and pharmaceutical services outsourcing refers to the strategic practice in which life sciences companies delegate specific functions or processes to third-party organizations. This model allows companies to focus on core competencies, enhance operational efficiency, and reduce costs by leveraging external expertise, infrastructure, and specialized resources.

The primary services in biotechnology and pharmaceutical services outsourcing include consulting, regulatory affairs, product design and development, auditing and assessment, product maintenance, training and education, and others. Consulting provides expert guidance to organizations on strategy, operations, compliance, and market entry. These services are applied across therapeutic areas such as oncology, neurology, cardiovascular, and infectious diseases, and are utilized by end users including pharmaceutical companies, biotechnology firms, and research institutions.

The biotechnology and pharmaceutical services outsourcing market includes revenues earned by entities by pharmacovigilance, medical writing, data management, analytical testing services, and formulation development. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.